Out-licensing: Biotechnology/Human Therapeutics

Up-to-date access to technology licensing opportunities worldwide.

Out-licensing
Browse

Licensing opportunities

Displaying 11..20 of 337 - per page Previous page Next page
Order by

A Secreted Therapeutic and Drug Discovery Target for Early Stage Osteoarthritis

A diagnostic and therapeutic secreted target protein that is upregulated in a subset of human patients with Osteoarthritis. It is a strong regulatory candidate for the transformation of maintenance chondrocytes into digestive aggravators of OA. More

Compositions and Methods for Increasing Recombinant Protein Yields Through the Modification of Cellular Properties

Compositions and methods for improving the growth characteristics of cells engineered to produce biologically active products such as antibodies or glycosylated proteins. More

NatureWise Biotech & Medicals Corporation: New compounds showing cell cycle gene regulation, with implications for new cancer therapies

Two new compounds having HDAC (histone deacetylase) inhibition capability have shown the effect of inducing re-differentiation of human brain and breast cancer cells both in vitro and in vivo. More

1,2,4-Benzothiadiazine derivatives

1,2,4-benzothiadiazine derivatives useful for the treatment of endocrinological system diseases such as hyperinsulinaemia and diabetes. More

APR BioFilm

Biotechnology Product for Wound Healing More

Novel Peptide Therapeutics for Bone Regeneration

Suite of proprietary collagen-binding peptides derived from bone sialoprotein (BSP) that are effective in promoting bone repair and regeneration. More

Protein (Biomolecule) Transduction Domain (PTD)

Rheumatoid arthritis More

Enhanced T-cell Activation by Costimulation: An Effective Immunotherapy for Cancer and Infectious Diseases

The present technology describes recombinant poxvirus vectors encoding at least three or more costimulatory molecules and TAAs. More

Dental Bone Grafts

Guided Bone Regeneration Membrane in Dental Surgery More

TNF-alpha Converting Enzyme Inhibitory Agents and Stimulatory Agents

This TACE inhibitory protein could be used as a new therapeutic agent against chronic inflammatory diseases that are mediated by TNF-alpha. More

Displaying 11..20 of 337 - per page Previous page Next page
Order by

Your selection

Industry sector: Biotechnology del; Human therapeutics del

Browse By

Therapeutic target: Accident and Trauma; Allergy; Blood and forming organs; Cardiovascular; Central Nervous System; Dermatological; Endocrinology; Gastrointestinal; Genetic disorders; Genito-urinary; Hospital and Surgery; Immune related disorders; Infectious diseases; Metabolism; Musculoskeletal; Oncology; Oral Health; Other therapeutic; Respiratory; Sensory organ
Development phase: Early Stage; Preclinical; Phase I; Phase I/II; Phase II; Phase III; Phase III/IV; Preregistration; Registered

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us